| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $812K | — | +3.4% |
| SG&A Expense | $1.1M | — | +2.1% |
| Operating Income | -$1.9M | — | -2.6% |
| Net Income | -$1.9M | — | -2.9% |
| EPS (Basic) | -$1.95 | — | +42.1% |
| EPS (Diluted) | -$1.95 | — | +42.1% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $3.7M | -28.7% | +18.2% |
| Current Assets | $4.0M | -27.4% | +11.1% |
| Total Assets | $5.6M | -21.4% | +6.1% |
| Current Liabilities | $1.4M | +26.3% | +7.4% |
| Total Liabilities | $1.4M | +23.9% | +0.4% |
| Stockholders' Equity | $4.2M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$1.6M | — | -34.1% |
| Capital Expenditures | $19K | — | — |
| Investing Cash Flow | -$15K | — | — |
| Financing Cash Flow | $124K | — | — |
| Free Cash Flow | -$1.6M | — | — |
| +8.1% |